By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues rose 35 percent year over year, and the firm cut its net loss by more than two-thirds.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $56.1 million for the three-month period ended Sept. 30, compared to $41.6 million for Q3 2009. It surpassed analysts' consensus estimate of $52.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.